Epizyme, Inc.

Envivo Pharmaceuticals, Inc.

Rugen Holdings (Cayman) Limited

Forum Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc.

Eragen Biosciences, Inc.

Luminex Corporation

Methylgene, Inc.

Other

Novartis Ag

Rfe Pharma LLC

Axovant Sciences Gmbh

Rugen Holdings Limited

Gideon Shapiro

Richard Chesworth

Lorna Helen Mitchell

Oscar Miguel Moradei

Amy Ripka

Lei Jin

Paula Ann Boriack-Sjodin

Kevin Wayne Kuntz

Robert E Babine

Simona Jurczyk

James Robert Prudent

David J Marshall

Christopher B Sherrill

Jerod L Ptacin

Kenneth William Duncan

Kerren Kalai Swinger

Muneki Kishida

Patricia Oliver-Shaffer

Gerhard Koenig

Takayuki Ishige

Jennifer K Grenier

Craig S Richmond

Dorothy G Flood

Matthew Gregory Bursavich

Andrew J McRiner

Silvana Leit

Yves Andre Chantigny

Pierre Tessier

David Smil

Patrick Beaulieu

John Mancuso

Michael G Natchus

Thomas Josef Troxler

Peter Neumann

Robert Deziel

Max Peter Seiler

Mark A Lockwood

Robert Déziel

Daniel Berney

Gary Robinson

Alan J Franklin

Simon Jurczyk

Robin Breckenridge

Disclosed are methods for treating NMDA receptor-mediated disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. NMDA receptor-mediated disorders include autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders.

Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders

Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R, R, R, R, R, R, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula: wherein L, R, G, G, G, and Gare as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

Carm1 inhibitors and uses thereof

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described. 

Arginine methyltransferase inhibitors and uses thereof

Disclosed are chemical entities of Formula (I), wherein Rand Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I). 

3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists

Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein X, R, R, R, R, R, R, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula: wherein L, R, G, G, G, and Gare as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

CARM1 inhibitors and uses thereof

Disclosed are chemical entities of Formula (I), wherein Rand Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).

Disclosed are chemical entities of formula I: wherein X, Y, Z, R, R, R, Rand Rare defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of formula I, and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of formula I.

Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists

Disclosed are chemical entities of Formula (I): wherein Rand Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting PRMT1 activity. Methods of using the compounds for treating PRMT1-mediated disorders are also described. 

PRMT1 inhibitors and uses thereof

Disclosed are chemical entities of Formula (I): wherein X, Y, Z, R, R, Rand Rare defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I). 

3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists

Growing community of inventors

Gainesville, FL, United States of America

Gideon Shapiro